# Noshaq

> Noshaq is a VC fund in Liège backing Biotechnology and Medical Device. See 15 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Liège, Belgium
- Total investments: 15
- Last investment: Jul 2026
- Lead investor: 20%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/noshaq-be
- Website: https://noshaq.be/en

Noshaq is a VC fund in Liège focused on Biotechnology and Medical Device. The province's economic redistribution and development are facilitated by the Noshaq group.

## Contacts

5 contacts available for Noshaq. Shizune tracks 3 team members at Noshaq. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/noshaq-7a35?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $5.4M–$43M |
| Series A | $5.3M–$19M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 20% |
| Medical Device | 3 | 20% |
| Manufacturing | 2 | 13% |
| Pharmaceutical | 2 | 13% |
| Renewable Energy | 2 | 13% |

31 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 4 | 27% |
| Series A | 3 | 20% |
| Funding Round | 3 | 20% |
| Pre-Seed | 2 | 13% |
| Series B | 1 | 7% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Belgium | 7 | 47% |
| France | 5 | 33% |
| United States | 1 | 7% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Fabian Marcq | COO | 0 | https://shizune.co/investors/profile/fabian-marcq |
| Gaëtan Servais | CEO | 5 | https://shizune.co/investors/profile/ga%C3%ABtan-servais |
| Hugues Danze | CCO | 0 | https://shizune.co/investors/profile/hugues-danze |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Brenus Pharma | Brenus Pharma is an allogeneic platform to generate immune therapy ambitioning to harness patient immune system & prevent cancer resistance over treatment. | $12.6M | Series A | Jul 20, 2026 |  |
| Standing Ovation | Standing Ovation develops food technology solutions using precision fermentation to produce animal-free dairy proteins for food manufacturing. The company creates casein proteins through engineered microorganisms, enabling the production of cheese and other dairy products without relying on traditional animal farming.Its core product, AdvancedCasein, is designed to replicate the functional, nutritional, and taste properties of conventional milk proteins while reducing dependence on livestock-based supply chains. The production process involves cultivating microorganisms, feeding them plant-based inputs, and extracting proteins that can be incorporated into standard dairy processing methods. Standing Ovation applies these proteins in the development of cheese alternatives that follow traditional cheesemaking techniques, allowing compatibility with existing manufacturing systems. The resulting products are lactose-free and aim to maintain similar texture and performance characteristics as conventional dairy ingredients in food applications. | $28.6M | Series B | Mar 31, 2026 |  |
| Vertical Compute | Vertical Compute offers chiplet-based technology that cuts data movement to achieve up to 80% energy savings. | $42.9M | Seed | Mar 04, 2026 |  |
| MYCOPHYTO | Co-created in July 2016 by Justine LIPUMA, PhD in microbiology, and Christine PONCET-DOISE, Senior Research Engineer at INRA, MYCOPHYTO is the result of 30 years of experimentation in biological crop protection. | $18.7M | Series A | Jan 12, 2026 |  |
| Sunrise | Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems. | $29.2M |  | Sep 25, 2025 |  |
| Dianosic | Dianosic was founded in 2017 and develops innovative solutions in the field of ENT (Ear, Nose & Throat), a $50 billion, double digit growth, and still largely underserved market. Our startup operates right at the frontier between Medtech and Biotech, as we see tremendous opportunities for drug-device combinations in this specialty. The projectoriginates from the ENT Department from the University Hospital of Strasbourg, where unmet clinical needs have been identified. Our main focus areas are Chronic Rhinitis, Chronic Sinusitis and intranasal bleeding (Epistaxis). Noteworthy, Dianosic has a strong French and German footprint in R&D and manufacturing.Dianosic’s strategic goal is to establish new standards of care in Chronic Rhinitis and Chronic Sinusitis with its drug-eluting Active Resorbable Scaffold (ARIS). This drug-device combination ARIS platform, developed with world renowned resorbable polymers experts, has the potential to establish new treatment paradigms. Moreover, our ARIS platform creates immense opportunities to create other verticals, especially in the field of chronic migraine and facial pain.Beside this, Dianosic commercialize an Asymmetric Intranasal inflatable solution (CAVI-T) for the treatment of intranasal bleeding, a widespread condition in ENT that affects 10% of the population. This CE marked and FDA registered technology addresses a clear unmet need and demonstrated our ability not only to develop a differentiated technology in record time, but also to successfully transition from R&D to Sales. We are currently present in relevant markets in EU and paving the way to launch in the U.S. in the mid term. Noteworthy, since our main call point is the ENT, CAVI-T prepares the ground for our upcoming ARIS platform. | $8.2M |  | Sep 05, 2025 |  |
| Signatur Biosciences | Signatur Biosciences is bringing molecular diagnostics to a whole new level. Founded in 2022. | $7M | Seed | Apr 28, 2025 |  |
| ARK Capture Solutions | ARK Capture Solutions is a cleantech company that specializes in decarbonization solutions to record low energy consumption. | $2.4M | Pre-Seed | Mar 25, 2025 |  |
| Pleevi | Pleevi focuses on optimizing EV charging solutions for large parking facilities. It offers an AI-powered software solution that intelligently schedules charging sessions. The system considers local energy generation, pricing, and building load constraints, delivering cheaper and greener charging sessions while ensuring drivers comfort. Drivers canbe confident that their vehicles will be fully charged by the time they are ready to depart. | $1M | Pre-Seed | Jan 30, 2025 |  |
| QustomDot | QustomDot is an advanced materials company that produces on-chip grade Quantum Dots (QDs) and assists customers in successfully integrating QDs into their products. QustomDot is headquartered in Ghent, Belgium. | $5.3M | Series A | Dec 09, 2024 |  |

10 of 15 investments shown.

## Co-investors
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 4 deals together
- [Crédit Agricole](https://shizune.co/investors/profile/credit-agricole) — VC Fund, 3 deals together
- [Sambrinvest](https://shizune.co/investors/profile/sambr-invest) — VC Fund, 3 deals together
- [WE International](https://shizune.co/investors/profile/we-international) — VC Fund, 3 deals together
- [CDG Invest](https://shizune.co/investors/profile/cdg-invest) — VC Fund, 2 deals together
- [Eurazeo](https://shizune.co/investors/profile/eurazeo-com) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Breakthrough Energy Ventures](https://shizune.co/investors/profile/breakthrough-energy-ventures) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund
- [Limburgse Reconversie Maatschappij](https://shizune.co/investors/profile/limburgse-reconversie-maatschappij) — VC Fund
- [Qbic Fund](https://shizune.co/investors/profile/qbic-fund) — VC Fund

## Featured in investor lists
- [Manufacturing Investors in Belgium](https://shizune.co/investors/manufacturing-investors-belgium)
- [Climate VC Funds in Belgium](https://shizune.co/investors/climate-vc-funds-belgium)
- [Energy Investors in Belgium](https://shizune.co/investors/energy-investors-belgium)
- [Energy VC Funds in Belgium](https://shizune.co/investors/energy-vc-funds-belgium)
- [Renewable Energy Investors in Belgium](https://shizune.co/investors/renewable-energy-investors-belgium)
- [Renewable Energy VC Funds in Belgium](https://shizune.co/investors/renewable-energy-vc-funds-belgium)

## FAQ

### What does Noshaq invest in?

Noshaq invests primarily in Biotechnology, Medical Device and Manufacturing startups, most often at Seed and Series A stage. Most of the 15 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Noshaq's check size?

Noshaq typically joins rounds of $5.4M–$43M at Seed and $5.3M–$19M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Noshaq participates in.

### How do I contact Noshaq?

Public channels for Noshaq include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Noshaq?

The team at Noshaq includes Fabian Marcq (COO), Gaëtan Servais (CEO) and Hugues Danze (CCO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co